StreetInsider.com News Articles

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Wed, 02 Sep 2026 08:30:00 -0400

SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.

2026 Cantor Global Healthcare Conference being held Wednesday, September 9^th to Saturday, September 12^th at the Waldorf Astoria in New York City. The Company will host a presentation at 9:10am ET on Friday, September 10^th.
The H.C. Wainwright 28^th Annual

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

Wed, 02 Sep 2026 08:30:00 -0400

2026 Cantor Global Healthcare Conference being held Wednesday, September 9^th to Saturday, September 12^th at the Waldorf Astoria in New York City. The Company will host a presentation at 9:10am ET on Friday, September 10^th.
The H.C. Wainwright 28^th Annual

Ensysce completes enrollment in final stage of opioid study

Mon, 31 Aug 2026 08:32:03 -0400

Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced the completion of enrollment in Part 3 of its PF614-MPAR-102 clinical study, the second study evaluating its MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology.

The study, supported by the National Institute on Drug Abuse (NIDA) under Award Number DA047682, was designed to characterize the drug's protective profile across a range of dosing scenarios. According to the company, clinical data published to date shows PF614-MPAR maintains consistent therapeutic plasma levels at normal doses while limiting exposure increases at supratherapeutic levels.

PF614-MPAR holds Breakthrough Therapy designation. The drug uses a chemical-control mechanism intended to provide therapeutic opioid exposure at

Ensysce completes enrollment in final stage of opioid study

Mon, 31 Aug 2026 08:32:03 -0400

PF614-MPAR holds Breakthrough Therapy designation. The drug uses a chemical-control mechanism intended to provide therapeutic opioid exposure at

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Mon, 31 Aug 2026 08:30:00 -0400

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, today announced completion of enrollment in the final stage of the PF614-MPAR-102 clinical study. The study evaluated its

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Mon, 31 Aug 2026 08:30:00 -0400

~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~

Form 8-K Ensysce Biosciences, For: Aug 25

Tue, 25 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260825/26975671.html

Form 8-K Ensysce Biosciences, For: Aug 25

Tue, 25 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260825/26975671.html

Form 8-K Ensysce Biosciences, For: Aug 24

Mon, 24 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260824/26969100.html

Form 8-K Ensysce Biosciences, For: Aug 24

Mon, 24 Aug 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260824/26969100.html

Form D Ensysce Biosciences,

Thu, 20 Aug 2026 14:14:00 -0400

si-local-file:///var/storage/secattach/20260820/26955560.html

Form D Ensysce Biosciences,

Thu, 20 Aug 2026 14:14:00 -0400

si-local-file:///var/storage/secattach/20260820/26955560.html

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Thu, 20 Aug 2026 08:00:00 -0400

~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~

~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~

SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today announced that it will host an educational symposium at PAINWeek 2026, entitled A New Era in Pain Therapeutics.

The symposium will present

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Thu, 20 Aug 2026 08:00:00 -0400

~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~

~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~

The symposium will present

Form SCHEDULE 13D/A Ensysce Biosciences, Filed by: GOWER BOB G

Tue, 18 Aug 2026 12:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26943025.html

Form SCHEDULE 13D/A Ensysce Biosciences, Filed by: GOWER BOB G

Tue, 18 Aug 2026 12:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26943025.html

Form 4 Ensysce Biosciences, For: Apr 23 Filed by: GOWER BOB G

Tue, 18 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260818/26940152.html

Form 4 Ensysce Biosciences, For: Apr 23 Filed by: GOWER BOB G

Tue, 18 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260818/26940152.html

Form 10-Q Ensysce Biosciences, For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921902.html

Form 10-Q Ensysce Biosciences, For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921902.html

Form 8-K Ensysce Biosciences, For: Aug 13

Thu, 13 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26921560.html

Form 8-K Ensysce Biosciences, For: Aug 13

Thu, 13 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260813/26921560.html

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 13 Aug 2026 16:15:00 -0400

Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome
Up to $77 million in new funding with the acquisition of Cy Biopharma
Company to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET

SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.

On August 6,

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 13 Aug 2026 16:15:00 -0400

On August 6,

Form 3 Ensysce Biosciences, For: Aug 05 Filed by: Morrison James William

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897767.html